StonvexLoading…
StonvexStonvexStonvexWhat you need to know right now
This is an algorithmic assessment of current technical conditions, not investment advice. Past performance does not guarantee future results.
Real-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-11 | $23.70 | $23.66 | -0.17% | 1.0M |
| 05-12 | $23.55 | $23.51 | -0.17% | 0.6M |
| 05-13 | $23.42 | $24.86 | +6.15% | 0.8M |
| 05-14 | $24.32 | $24.63 | +1.27% | 0.5M |
| 05-15 | $22.55 | $22.87 | +1.42% | 0.9M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $1.74M | $24.05M | $22.12M | $20.05M |
Operating Income | $-98.41M | $-453.80M | $-357.36M | $-242.07M |
Net Income | $-93.05M | $-243.32M | $-150.39M | $59.32M |
EPS (Diluted) | $-0.74 | $-2.86 | $-1.92 | $-0.61 |
Total Assets | $671.59M | $411.94M | $488.01M | $610.92M |
Total Liabilities | $104.57M | $110.64M | $103.24M | $125.60M |
Cash & Equivalents | $63.88M | $89.67M | $65.26M | $151.75M |
Free Cash Flow OCF − CapEx | $-87.25M | $-370.18M | $-298.27M | $-187.36M |
Shares Outstanding | 125.05M | 85.03M | 78.47M | 65.44M |
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.
Alumis Inc is a clinical-stage biopharmaceutical company with an initial focus on developing its two Tyrosine Kinase 2 ("TYK2") inhibitors: envudeucitinib ("envu"), an allosteric TYK2 inhibitor for the treatment of PsO and SLE; and A-005, a central nervous system ("CNS") penetrant allosteric TYK2 inhibitor, to offer the therapeutic benefit of TYK2 inhibition within the CNS for a broad range of neuroinflammatory and neurodegenerative diseases.